Challenges of Systemic Therapy Investigations for Bone Sarcomas.

Area of Science:

• Oncology
• Genetics
• Pharmacology

Background:

• Bone sarcoma is a rare malignancy (~0.2% of cancers) with diverse histological types and distinct genomic profiles.
• Most identified mutations in bone sarcomas are non-actionable, and even potentially targetable mutations show limited efficacy in clinical trials.
• Progress in systemic therapies, including molecular targeted therapies, for bone sarcomas lags behind other solid tumors.

Purpose of the Study:

• To review the challenges and current evidence regarding targeted drug investigations for bone sarcomas.
• To highlight efforts aimed at overcoming obstacles in developing new therapies for this rare cancer.
• To discuss the specific issues related to pediatric and young adult bone sarcoma patients in clinical trials.

Main Methods:

• Review of existing clinical evidence and research on targeted therapies for bone sarcoma.
• Analysis of challenges in drug development, including mutation actionability and clinical trial design.
• Examination of strategies to improve data collection and pediatric drug evaluation.

Main Results:

• Significant hurdles exist in identifying actionable targets and achieving therapeutic responses in bone sarcoma clinical trials.
• Patient recruitment for clinical trials, particularly randomized ones, is difficult, especially for pediatric/adolescent and young adult populations.
• Current efforts focus on enhancing registry systems, leveraging real-world data, and employing pediatric extrapolation for drug development.

Conclusions:

• Targeted drug development for bone sarcoma is hindered by a lack of actionable mutations and clinical trial recruitment challenges.
• Specific considerations for pediatric populations, including tolerability and dosing, are crucial for advancing new therapies.
• Improvements in data infrastructure and adaptive trial designs are essential to accelerate the development of effective treatments for bone sarcoma.